Cancer
fromThe New England Journal of Medicine
1 day agoFirst-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations | NEJM
Sunvozertinib first-line therapy improved progression-free survival and objective response versus carboplatin-pemetrexed in advanced EGFR exon 20 insertion NSCLC, with higher grade 3+ adverse events.